Emile Voest, MD, PhD (chairman)
Emile Voest is professor of Medical Oncology and serves on the executive board of the Netherlands Cancer Institute in Amsterdam as Medical Director.
He also serves as chair of the Center for Personalized Cancer Treatment (a joint effort of the UMC Utrecht, Erasmus MC and NKI/AvL), as chair of the scientific council of the Dutch Cancer Society (KWF), as chair of the scientific council of the Pediatric Oncology Foundation (KiKa) and as medical director on the board of the HUB Foundation for Organoid Technology and Stem Cell Technology.
His translational research has focused on improving systemic treatment for patients with cancer. This includes the clinical development of targeted agents, discovery and validation of biomarkers with emphasis on genetics and organoids, and identification of new targets of treatment to overcome chemoresistance.
Dr Voest was registered as a medical doctor in 1985. He became board certified as an internist in July 1993, and as a medical oncologist in January 1995. He completed his PhD program on the enhancement of the efficacy of anthracyclines by modulation of iron metabolism in tumor cells in June 1993 (cum laude). In 1994 and 1995 he was a postdoctoral fellow of the Dutch Cancer Society. As a postdoctoral fellow he joined the laboratory of Dr. Judah Folkman, Children’s Hospital, Harvard Medical School, Boston and worked on endogenous inhibitors of angiogenesis. Thereafter he worked at the Netherlands Cancer Institute in Amsterdam on high dose chemotherapy. In November 1999 he became a full professor in Medical Oncology. He has several patents to his name and founded the spin-out company PIFA Therapeutics that investigates reversal of resistance to anti-cancer treatment. He is co-author of approximately 200 manuscripts.
Dr Voest serves as one of the Team Leaders in the Stand up to Cancer International Translational Research Grant “Prospective Use of DNA-guided Personalized Cancer Treatment”.